Acceleron Clinical Trials

Clinical Trials

Clinical Trials

At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.

  • We are developing luspatercept, our lead product candidate, for the treatment of the chronic anemias in myelodysplastic syndromes (MEDALIST Phase 3 trial ongoing and COMMANDS Phase 3 trial planned), beta-thalassemia (BELIEVE Phase 3 and BEYOND Phase 2 trials ongoing), and myelofibrosis (Phase 2 trial ongoing). The goal of these trials is to reduce or eliminate the need for regular red blood cell transfusions. Luspatercept is currently under a global partnership with Celgene.
  • ACE-083 is being studied in two, two-part Phase 2 trials; one trial is being conducted in facioscapulohumeral muscular dystrophy (FSHD) and the other is being conducted in Charcot-Marie-Tooth (CMT) disease.
  • In our pulmonary program, our newest disease focus area, we recently initiated the PULSAR Phase 2 trial in pulmonary arterial hypertension.

The clinical trials listed below are Acceleron or partner-sponsored trials that are actively recruiting patients. Each trial in the list contains a link to, where you will find a full description and contact information.

Drug Study Phase Disease
Luspatercept MEDALIST Phase III Lower-Risk MDS
Luspatercept BELIEVE Phase III Beta-Thalassemia
Luspatercept Phase II Extension MDS
Luspatercept Phase II Extension Beta-Thalassemia
Luspatercept Phase II Beta-Thalassemia
Luspatercept BEYOND Phase II Beta-Thalassemia
Luspatercept Phase II Anemia in Lower-Risk MDS
Luspatercept Phase II Myelofibrosis
Sotatercept Phase II Myelofibrosis
ACE-083 Phase II Facioscapulohumeral Muscular Dystrophy
ACE-083 Phase II Charcot-Marie-Tooth Disease
Sotatercept PULSAR Phase II Pulmonary Arterial Hypertension
ACE-2494 Phase I Healthy Volunteers
Acceleron trials listed as recruiting or active on